Abstract We report a case that demonstrates the efficacy of radioimmunotherapy (RIT) with radioiodinated rituximab ( 131
Introduction
Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent subtypes of non-Hodgkin lymphoma (NHL) worldwide [1] . Significant improvements in the outcome of patients with DLBCL have been achieved with the incorporation of rituximab into standard chemotherapeutic regimens. Although gene expression analyses revealed the biological heterogeneity of DLBCL, CD20-targeted therapy has been proved to be effective. Fu et al. reported that additional rituximab was effective in both the germinal center B-cell-like and nongerminal center B-cell-like subtypes of DLBCL [2] .
The goal of radioimmunotherapy (RIT) is to target tumors more effectively while sparing normal cells by using a radiolabeled monoclonal antibody (mab). There are two commercially available anti-CD20 antibodies for treating patients with relapsed NHL, one was radiolabeled with yttrium-90 ( 90 Y-ibritumomab tiuxetan; Zevalin; Biogen Idec, Inc., San Diego, CA, and Schering AG, Berlin, Germany) and the other was radiolabeled with iodine-131 ( 131 I-tositumomab; Bexxar; Corixa Corp., Seattle, WA). These radioimmunotherapeutic agents have resulted in promising outcomes for the overall response rate of up to 80 % and prolonged response duration of more than 1 year [3, 4] . Turner et al. reported a similar response when RIT was performed using 131 I-rituximab, with an overall response rate of 76 % (high CR or unconfirmed CR rate of 53 %) after a single treatment with 131 I-rituximab in a total of 91 patients with relapsed or refractory NHL [5] . However, the efficacy of Here, we report a case in which RIT using 131 I-rituximab was used to treat a patient with DLBCL who had relapsed after
Case Report
A 79-year-old male patient was admitted to an outside hospital because of a left upper neck mass. After excisional biopsy, he was diagnosed with CD20-positive DLBCL in May 2005. Immunochemistry results indicated that the mass was positive for leucocyte common antigen, CD20 and CD79a and negative for cytokeratins, CD15, CD30 and anaplastic lymphoma kinase 1. Involvement of the left cervical level II lymph node and each of the lower paratracheal, preaortic and right hilar lymph nodes was noted. However, bone marrow involvement was not detected. The patient had diabetes mellitus, hypertension and coronary heart disease and had undergone percutaneous coronary intervention at the mid-left anterior descending artery in June 2003. He had no relevant family history or drinking behavior. However, he was a heavy smoker.
The patient had achieved CR after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy, which was initiated in May 2005. However, he was diagnosed with relapsed DLBCL in 2007. At that time, positron emission tomography-computed tomography (PET-CT) showed lymphoma involvement in the left lower cervical lymph node, the left internal mammary node, both axillary nodes, both lower paratracheal nodes, the aortopulmonary window, the paraaortic node, the left internal mammary node, the subcarinal node, both hilar nodes, right interlobar lymph nodes and the spleen. Although the patient achieved a second CR after one cycle of However, in February 2011, the patient experienced a third relapse in the left neck level II, mediastinal, axillary, left gastric, peripancreatic, portocaval, paraaortic, left external iliac and inguinal lymph nodes, and in both lungs, as shown in Fig. 1a . At this point, he was referred to our institution to discuss the possibility of enrolling in an ongoing phase II trial of RIT with 131 I-rituximab for relapsed/refractory NHL. However, he was older than the maximum age criterion for the trial; thus, he was administered 131 I-rituximab as part of the group outside of the clinical trial. Although he was not considered part of the clinical trial, treatment was administered in accordance with the predefined study protocol [6] . Before infusing the unlabeled rituximab, potassium iodine was administered to prevent thyroid uptake of 131 I at least 24 h before RIT. He received unlabeled rituximab (70 mg) intravenously for 5 min in the radiation isolation room, followed by the therapeutic dose (7400 MBq, 200 mCi) of 131 I-labeled rituximab intravenously for 15 min. During treatment, we monitored the patient's heart and respiratory rates and performed electrocardiography.
The toxicity experienced by the patient was principally hematological (grade 1 thrombocytopenia). His laboratory results before the first cycle of 131 I-rituximab were as follows: white blood cell count, 4820/μl, hemoglobin level, 11.9 g/dl and platelet count, 150×10 9 /l. His platelet count had fallen to 103×10 9 /l just before the second cycle of 131 I-rituximab, but during the first day of that cycle, it fell to its lowest value of 86×10 9 /l. The time to platelet nadir was thus 7 weeks. Figure 1 shows the serial images of I-rituximab, a PET-CT scan showed that the uptake in the hypermetabolic lesions of both lungs had decreased (standard uptake value: 1.5), and no other hypermetabolic lesions were observed (Fig. 1c) . However, the patient experienced progression after the third cycle of 131 I-rituximab in July 2011. After three cycles of 131 Irituximab, PET-CT revealed two focal hypermetabolic lymph nodes in the left inguinal area (Fig. 1d) .
The progression-free survival of the patient was thus 5 months. He was treated with external beam radiation therapy directed to the left inguinal lymph node. After 25 fractions of radiation therapy (total radiation dose 45 Gy), he had achieved CR and was then treated with oral cyclophosphamide between December 2011 and July 2012. There has been no evidence of recurrence up to March 2013 (Fig. 1e) .
Discussion
RIT has emerged as a promising treatment option for patients with refractory or relapsed lymphoma. One of the first radioimmunotherapeutic drugs, I-rituximab has not been approved, it is administered for relapsed/refractory NHL in the clinical trial setting, and it has shown promising results to date [5] . Kang et al. also reported that single RIT with 131 I-rituximab gave a modest response (29 %; 7 of 24 patients) among Korean patients with relapsed/refractory B-cell NHL [6] .
Despite RIT having been used to successfully treat patients with indolent NHL, there have been only a few studies on its use in patients with DLBCL. Morschhauser et al. reported that 90 Y-ibritumomab tiuxetan used as a second-line therapy for patients with relapsed DLBCL who had previously been treated with R-CHOP as a first-line therapy contributed to an overall response rate of 23 % (3 of 13 patients) [7] . 90 Yibritumomab has also been evaluated as a post-remission therapy in high-risk patients [8] or elderly patients with DLBCL [9, 10] . However, the use of 90 Y-ibritumomab as a consolidation treatment for DLBCL remains controversial.
131
I-tositumomab has mainly been studied as a part of a conditioning regimen for autologous hematopoietic stem cell transplantation for relapsed DLBCL. This includes a recent phase III study in which the progression-free survival and overall survival of patients treated with a 131 I-tositumomabcontaining conditioning regimen were not significantly different compared to that of those treated with a rituximabcontaining regimen [11] .
Despite these advances, the use of 131 I-rituximab as a basis for the RIT of DLBCL has not been widely studied thus far. Furthermore, there have been no reports on RIT using I-rituximab in a total of 142 patients with lymphoma was mainly self-limited myelosuppression, with grade 4 thrombocytopenia and grade 4 neutropenia in 6 % and 10 % of cases, respectively [14] . The only toxicity observed in our patient was a grade 1 thrombocytopenia, without anemia and neutropenia. The time to the platelet nadir was 7 weeks. When the PET-CT scan revealed high uptake by the inguinal lymph nodes after the third treatment with 131 I-rituximab, suggesting progressive disease, we decided not to perform tissue diagnosis because of his old age, heart problem and ongoing palliation. However, there is still a possibility that a high uptake by inguinal lymph nodes could be due to benign lesions rather than true progression, given the disease course after subsequent local radiation therapy and oral chemotherapy.
Despite a limitation, our case is noteworthy as it suggests that 131 I-rituximab results in only acceptable toxicity and is a possible salvage therapy after the failure of RIT using commercial conjugates such as Further prospective studies are needed to evaluate the efficacy of 131 I-rituximab and to compare the efficacy of different sequentially applied radioimmunotherapeutic drugs for patients with DLBCL. 
